Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

15.70 +1.44 (+10.10%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2026 Add to My Watchlist

Price and Volume

Volume	11,483,162
Open	16.65
Bid (Size)	15.70 (100)
Ask (Size)	16.28 (2,200)
Prev. Close	14.26
Today's Range	15.69 - 17.47
52wk Range	2.930 - 17.47
Shares Outstanding	121,613,181
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

May 27, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Is Relay Therapeutics a Buy After Promising Trial Results? ↗

May 22, 2026

Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy.

Via The Motley Fool

Performance

YTD	+91.9%	+91.9%
1 Month	+19.9%	+19.9%
3 Month	+59.4%	+59.4%
6 Month	+109.6%	+109.6%
1 Year	+393.7%	+393.7%

More News

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

May 20, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Why Relay Therapeutics Stock Popped on Wednesday ↗

May 20, 2026

Via The Motley Fool

Relay Therapeutics (NASDAQ:RLAY) Beats Q1 Estimates but Slips on Wider Loss and Lack of Guidance ↗

May 05, 2026

Via Chartmill

Relay Therapeutics Inc (NASDAQ:RLAY) Beats Q4 Revenue Estimates, Outlines Pivotal 2026 for Zovegalisib ↗

February 26, 2026

Via Chartmill

Relay Therapeutics Announces Proposed Public Offering of Common Stock

May 19, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

May 19, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million ↗

May 18, 2026

Via The Motley Fool

Energy Vault Stock Has Surged 500%. One Major Holder Just Sold 3 Million Shares ↗

May 18, 2026

Via The Motley Fool

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

May 05, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

April 29, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

April 27, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

April 02, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗

March 19, 2026

Via The Motley Fool

Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗

March 19, 2026

Via The Motley Fool

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

March 16, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗

February 27, 2026

Via The Motley Fool

Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗

February 27, 2026

Via The Motley Fool

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

February 26, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March

February 23, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Via The Motley Fool

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

February 23, 2026

Via The Motley Fool

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

February 23, 2026

Via The Motley Fool

Frequently Asked Questions

Is Relay Therapeutics, Inc. - Common Stock publicly traded?

Yes, Relay Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Relay Therapeutics, Inc. - Common Stock trade on?

Relay Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Relay Therapeutics, Inc. - Common Stock?

The ticker symbol for Relay Therapeutics, Inc. - Common Stock is RLAY on the Nasdaq Stock Market

What is the current price of Relay Therapeutics, Inc. - Common Stock?

The current price of Relay Therapeutics, Inc. - Common Stock is 15.70

When was Relay Therapeutics, Inc. - Common Stock last traded?

The last trade of Relay Therapeutics, Inc. - Common Stock was at 06/02/26 04:00 PM ET

What is the market capitalization of Relay Therapeutics, Inc. - Common Stock?

The market capitalization of Relay Therapeutics, Inc. - Common Stock is 1.91B

How many shares of Relay Therapeutics, Inc. - Common Stock are outstanding?

Relay Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.